Potassium voltage-gated channel subfamily A member 1 (KCNA1) (KCNA1)

Potassium voltage-gated channel subfamily A member 1 (Kv1.1) is a critical component of the Shaker-related family of voltage-gated potassium channels, primarily localized in the juxtaparanodal regions of axons and nerve terminals [1, 4]. It functions as a delayed rectifier, mediating the efflux of potassium ions to repolarize the cell membrane following an action potential, thereby regulating neuronal excitability and synaptic transmission [1, 2]. Mutations in the KCNA1 gene are associated with a spectrum of neurological channelopathies, most notably episodic ataxia type 1 (EA1), which is characterized by stress-induced attacks of ataxia and persistent myokymia [6, 11]. Kv1.1 is also implicated in epilepsy and is a significant factor in the risk of sudden unexpected death in epilepsy (SUDEP) due to its role in both brain and autonomic cardiorespiratory control [7, 15, 17]. Pharmacologically, Kv1.1 and its family members (such as Kv1.3 in the immune system) are targeted by various small molecules and toxins; for instance, 4-aminopyridine is used to improve motor function in multiple sclerosis by blocking these channels [1, 10, 13]. Current research focuses on developing selective activators to treat hyperexcitability and specific blockers for autoimmune and oncological applications [4, 6, 9].

Other names

Kv1.1Voltage-gated potassium channel 1.1Shaker-related subfamily member 1RBK1HUK1MBK1Kv1 family

Drugs targeting Kv1 channels primarily act as pore blockers to prolong action potentials and enhance neurotransmission, or as activators to reduce neuronal hyperexcitability. Some modulators work by inhibiting channel inactivation through the disruption of alpha-beta subunit interactions or by shifting the voltage-dependence of activation.